NanoSphere Health Sciences developed the first and only patent-pending nanoparticle delivery system platform for medical cannabis. Under the brand “Evolve”, NanoSphere has already launched its award-winning NanoSerum™ product for the recreational and medical cannabis markets in Colorado. NanoSerum utilizes the NanoSphere Delivery System™ (NDS) and is the first clinically-tested transdermal, cannabis product to relieve pain in minutes. We intend to build on that success by opening new markets for Evolve™ and developing new product applications. For more information on NanoSerum, visit www.evolveformulas.com.

Concentrated liquid “NanoSpheres” deliver plant extracts of cannabis and purified cannabinoids in convenient standardized dosages with increased bioavailability, bioactivity, and therapeutic potential. At the same time these natural phospholipid nanoparticles decrease the adverse effects of cannabis.

While significant advancements and investments have been made in the medical cannabis industry. We are the first to apply nanotechnology to improve the bioavailability and efficacy of cannabis extracts and standardize dosages. This disruptive technology introduces a significant advancement in the medical and recreational cannabis markets, and meets the regulatory demands for product purity, uniformity, and the reporting of active cannabinoid levels.

Seamless Market Integration

NanoSphere’s business model integrates into the regulatory and product manufacturing chain-of-possession. We are partnering with cannabis growers, extractors, product manufacturers, and dispensaries in creating a superior branded cannabis product. The ‘NanoSphere Delivery System’ platform satisfies the regulatory requirements for quality control, standardized cannabis dosages, full disclosure labeling, and complete transparency.   

NanoSpheres™ Revolutionizes How Cannabis Delivers Benefits

The NanoSphere Delivery System revolutionizes how cannabis delivers its benefits. Liquid NanoSpheres nanosize, encapsulate, and rapidly deliver concentrated plant extracts and cannabis, purified cannabinoids, with increased bioavailability, bioactivity, and therapeutic potential in standardized dosages printed on the product labels. At the same time, the biocompatible, phospholipid nanoparticle spheres (less than 70 nm in diameter) help decrease the adverse effects of cannabinoids.

NanoSphere’s cannabinoid products are uniquely designed to be administered intra-orally, intra-nasally, and transdermally in precision dose-metered dispensers. The convenient-to-use liquid NanoGels™ bypass the GI tract and avoid first pass liver metabolism. The NanoSphere’s dynamic membrane structure of purified essential phospholipids efficiently transports cannabinoids into the circulatory system and across the cell membranes to bind endocannabinoid and synergistic receptors. 

Solving the Problems of Cannabis Therapies

The problems with existing cannabis therapies are glaringly apparent. Cannabinoids are fat-soluble compounds with low solubility and dissolution in water. They have low oral bioavailability of only 6% and are inefficiently delivered to cannabinoid receptors in the cell membranes. Plus, certain cannabinoids produce adverse effects that include cognitive impairment, cardiovascular disturbances, and developing a tolerance to cannabinoid treatments.

The company’s patent-pending NanoSphere phospholipid nanoparticle encapsulation of cannabinoids provides practical solutions for cannabinoid therapy with benefits of:

  • Standardized dose-metered dosages
  • Higher concentration of bioactive cannabinoids
  • Increased bioavailability of cannabinoids (2-fold to 8-fold)
  • Decreased dosages (2-fold to 8-fold)
  • Decreased adverse effects
  • Decreases developing a tolerance to cannabis from prolonged use
  • More efficacious cannabinoid therapy and medical cannabis treatments
  • Improved cannabinoid-to-receptor binding and signal transduction
  • Enhanced therapeutic value
  • And safer, long-term use